The clinical outcomes are complex and often involve multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging inspections, laboratory tests and pathological evaluations.
The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment plans for the treatment and management of autoimmune pancreatitis 1 require individualized development, usually including multidimensional management such as drug therapy, rehabilitation, regular follow-up visits. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adapted to timely regimens according to changes in disease. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of autoimmune pancreatitis type 1. 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.